Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
BackgroundIn recent years, newly discovered potential biomarkers have great research potential in the diagnosis, disease activity prediction, and treatment of systemic lupus erythematosus (SLE).ObjectiveIn this study, a scoping review of potential biomarkers for SLE over several years has identified the extent to which studies on biomarkers for SLE have been conducted, the specificity, sensitivity, and diagnostic value of potential biomarkers of SLE, the research potential of these biomarkers in disease diagnosis, and activity detection is discussed.MethodsIn PubMed and Google Scholar databases, “SLE,” “biomarkers,” “predictor,” “autoimmune diseases,” “lupus nephritis,” “neuropsychiatric SLE,” “diagnosis,” “monitoring,” and “disease activity” were used as keywords to systematically search for SLE molecular biomarkers published from 2020 to 2024. Analyze and summarize the literature that can guide the article.ConclusionsRecent findings suggest that some potential biomarkers may have clinical application prospects. However, to date, many of these biomarkers have not been subjected to repeated clinical validation. And no single biomarker has sufficient sensitivity and specificity for SLE. It is not scientific to choose only one or several biomarkers to judge the complex disease of SLE. It may be a good direction to carry out a meta‐analysis of various biomarkers to find SLE biomarkers suitable for clinical use, or to evaluate SLE by combining multiple biomarkers through mathematical models. At the same time, advanced computational methods are needed to analyze large data sets and discover new biomarkers, and strive to find biomarkers that are sensitive and specific enough to SLE and can be used in clinical practice, rather than only staying in experimental research and data analysis.
BackgroundIn recent years, newly discovered potential biomarkers have great research potential in the diagnosis, disease activity prediction, and treatment of systemic lupus erythematosus (SLE).ObjectiveIn this study, a scoping review of potential biomarkers for SLE over several years has identified the extent to which studies on biomarkers for SLE have been conducted, the specificity, sensitivity, and diagnostic value of potential biomarkers of SLE, the research potential of these biomarkers in disease diagnosis, and activity detection is discussed.MethodsIn PubMed and Google Scholar databases, “SLE,” “biomarkers,” “predictor,” “autoimmune diseases,” “lupus nephritis,” “neuropsychiatric SLE,” “diagnosis,” “monitoring,” and “disease activity” were used as keywords to systematically search for SLE molecular biomarkers published from 2020 to 2024. Analyze and summarize the literature that can guide the article.ConclusionsRecent findings suggest that some potential biomarkers may have clinical application prospects. However, to date, many of these biomarkers have not been subjected to repeated clinical validation. And no single biomarker has sufficient sensitivity and specificity for SLE. It is not scientific to choose only one or several biomarkers to judge the complex disease of SLE. It may be a good direction to carry out a meta‐analysis of various biomarkers to find SLE biomarkers suitable for clinical use, or to evaluate SLE by combining multiple biomarkers through mathematical models. At the same time, advanced computational methods are needed to analyze large data sets and discover new biomarkers, and strive to find biomarkers that are sensitive and specific enough to SLE and can be used in clinical practice, rather than only staying in experimental research and data analysis.
Background This study revealed the role of serum oxidative stress regulators such as sKL, Nrf2 and GSK3β, in the formation of calcium oxalate (CaOx) kidney stones. Methods Clinical data and blood samples were collected from 148 patients with CaOx kidney stones and 151 healthy persons.The levels of sKL, Nrf2, NQO-1, HO-1 and GSK3β in serum were determined by enzyme-linked immunosorbent assay (ELISA).The independent sample t test and rank sum test were used to compare the two sets of data.Spearman correlation analysis was used to evaluate the correlation between serum sKL and levels of Nrf2, NQO-1, HO-1 and GSK3β in patients with CaOx kidney stones.Logistic regression analysis was used to determine the factors affecting the occurrence of CaOx kidney stones. ROC curve was used to evaluate the value of oxidative stress markers in the diagnosis of CaOx kidney stones. Results There were statistically significant differences in age, BMI, serum levels of sKL, Nrf2, HO-1, NQO-1, GSK3β, potassium, sodium and magnesium between healthy group and CaOx group (P<0.05).Correlation analysis showed that serum sKL level was positively correlated with NQO-1 (r = 0.207, P = 0.011) and serum Ca2+ (r = 0.17, P = 0.13), and negatively correlated with GSK3β (r=-0.206, P = 0.012).Logistic regression showed that increased serum HO-1 and NQO-1 levels were protective factors for the occurrence of CaOx kidney stones (P<0.05), and increased BMI and serum GSK3β levels were risk factors for the occurrence of CaOx kidney stones(P<0.05).The combined ROC curve analysis of the three indexes showed that the combined sensitivity (0.85), specificity (0.70) and AUC (0.84) of serum HO-1 + NQO-1 + GSK3β were significantly higher than the combined detection of single or two indexes, and the difference was statistically significant (P<0.05). Conclusion The serum levels of sKL, Nrf2, HO-1, NQO-1 are decreased in patients with CaOx kidney stones, and the serum levels of GSK3β are increased.Serum sKL level was positively correlated with NQO-1 and negatively correlated with GSK3β.The elevated levels of serum HO-1 and NQO-1 are protective factors and GSK3β and BMI are risk factors for the development of CaOx kidney stones.Serum HO-1 + NQO-1 + GSK3β is a suitable combination for the serologic diagnosis of CaOx kidney stones.
Background Diabetes kidney disease (DKD) is a common complication of diabetes and is currently considered the primary cause of end-stage renal disease. Ferroptosis has been found to participate in the development of DKD. However, no ferroptosis-related markers have been evaluated in human DKD samples. This study aimed to examine the ferroptosis-related pathological alterations in DKD samples. Methods This study enrolled patients with DKD at the Third Hospital of Hebei Medical University between January 2018 and December 2022, of whom 30 were diagnosed with DKD and 10 with non-DKD (CON). Clinical data of patients were collected, and hematoxylin-eosin staining (H&E), PASM, and immunohistochemical staining were performed to evaluate pathological changes and the expression of ferroptosis-related proteins, including GPX4, ACSL4, Nrf2, TfR1, FTH, and FTL. Results Compared with the CON group, patients with DKD exhibited significantly elevated serum creatinine levels and reduced eGFR ( P < 0.05). Iron content and the expression of the ferroptosis-related protein ACSL4 were significantly increased, while the expression of Nrf2 was significantly decreased in the renal tissues of patients with DKD ( P all < 0.05). There were no differences in the expression of GPX4, TfR1, FTH, or FTL between the two groups. Nrf2 and ACSL4 expression were influential factors in the occurrence of DKD and both exhibited diagnostic value for DKD. Nrf2 was a protective factor (OR, < 1), whereas ACSL4 was a risk factor (OR, > 1). Conclusion Ferroptosis-promoting gene profile was identified in DKD renal samples, indicating that ferroptosis may participate in the pathogenesis of DKD. The expression levels of Nrf2 and ASCL4 in the kidneys are related to the severity and progression of DKD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.